New Insights into the Mechanisms of Action of Cotinine and its Distinctive Effects from Nicotine

Neurochemical Research

Volumn 40, Issue 10, 2014, Pages 2032-2046

  Grizzell, J Alex ^a,b   Echeverria, Valentina ^a,b,c  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSIDAD AUTÓNOMA DE CHILE   (Chile)

Author keywords

Cotinine; Nicotine; Nicotinic receptors; Synaptophysin; Tobacco

Indexed keywords

COTININE; NICOTINE; ANTIDEPRESSANT AGENT; NICOTINIC RECEPTOR;

ANTIDEPRESSANT ACTIVITY; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN FUNCTION; BRAIN REGION; COGNITION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SELF ADMINISTRATION; EMOTION; ESTROGEN METABOLISM; EXECUTIVE FUNCTION; HUMAN; LONG TERM POTENTIATION; MAXIMUM PLASMA CONCENTRATION; MEMORY; NERVE CELL PLASTICITY; NERVOUS SYSTEM FUNCTION; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TOBACCO CONSUMPTION; ANIMAL; COGNITION DISORDERS; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; COGNITION; COGNITION DISORDERS; COTININE; HUMANS; NICOTINE; RECEPTORS, NICOTINIC;

EID: 84946488629     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-014-1359-2     Document Type: Review

References (205)

1. Gately I (2007) Tobacco: A cultural history of how an exotic plant seduced civilization. Grove Press, New York
2. Peto R, Lopez AD, Boreham J, Thun M, Heath C Jr, Doll R (1996) Mortality from smoking worldwide. Br Med Bull 52:12–21
3. Balls EK (1962) Early uses of California plants. Univ of California Press, Oakland
4. Mineur YS, Picciotto MR (2010) Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis. Trends Pharmacol Sci 31:580–586
5. Ziedonis D, Hitsman B, Beckham JC, Zvolensky M, Adler LE, Audrain-McGovern J, Breslau N, Brown RA, George TP, Williams J, Calhoun PS, Riley WT (2008) Tobacco use and cessation in psychiatric disorders: National Institute of Mental Health report. Nicotine Tob Res 10:1691–1715
6. Leonard S, Adler LE, Benhammou K, Berger R, Breese CR, Drebing C, Gault J, Lee MJ, Logel J, Olincy A, Ross RG, Stevens K, Sullivan B, Vianzon R, Virnich DE, Waldo M, Walton K, Freedman R (2001) Smoking and mental illness. Pharmacol Biochem Behav 70:561–570
7. Rasmusson AM, Picciotto MR, Krishnan-Sarin S (2006) Smoking as a complex but critical covariate in neurobiological studies of posttraumatic stress disorders: a review. J Psychopharmacol 20:693–707
8. de Leon J, Tracy J, McCann E, McGrory A, Diaz FJ (2002) Schizophrenia and tobacco smoking: a replication study in another US psychiatric hospital. Schizophr Res 56:55–65
9. Diaz FJ, Velasquez DM, Susce MT, de Leon J (2008) The association between schizophrenia and smoking: unexplained by either the illness or the prodromal period. Schizophr Res 104:214–219
10. D’Souza MS, Markou A (2012) Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology 62:1564–1573
11. Cataldo JK, Prochaska JJ, Glantz SA (2010) Cigarette smoking is a risk factor for Alzheimer’s disease: an analysis controlling for tobacco industry affiliation. J Alzheimers Dis 19:465–480
12. Brenner DE, Kukull WA, van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB (1993) Relationship between cigarette smoking and Alzheimer’s disease in a population-based case–control study. Neurology 43:293–300
13. Hellstrom-Lindahl E, Mousavi M, Ravid R, Nordberg A (2004) Reduced levels of Abeta 40 and Abeta 42 in brains of smoking controls and Alzheimer’s patients. Neurobiol Dis 15:351–360
14. Jacobsen LK, Mencl WE, Constable RT, Westerveld M, Pugh KR (2007) Impact of smoking abstinence on working memory neurocircuitry in adolescent daily tobacco smokers. Psychopharmacology 193:557–566
15. Papke RL (2014) Merging old and new perspectives on nicotinic acetylcholine receptors. Biochem Pharmacol 8:1–11
16. Hukkanen J, Jacob P, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57:79–115
17. Moran VE (2012) Cotinine: beyond that expected, more than a biomarker of tobacco consumption. Front Pharmacol 3:173
18. Hatsukami DK, Grillo M, Pentel PR, Oncken C, Bliss R (1997) Safety of cotinine in humans: physiologic, subjective, and cognitive effects. Pharmacol Biochem Behav 57:643–650
19. Langley JN (1905) On the reaction of cells and of nerve-endings to certain poisons, chiefly as regards the reaction of striated muscle to nicotine and to curari. J Physiol 33:374–413
20. Rang HP (2006) The receptor concept: pharmacology’s big idea. Br J Pharmacol 147(Suppl 1):S9–S16
21. Dale H (1937) Transmission of nervous effects by acetylcholine: Harvey Lecture, May 20, 1937. Bull N Y Acad Med 13:379
22. Quik M, Bordia T, O’Leary K (2007) Nicotinic receptors as CNS targets for Parkinson’s disease. Biochem Pharmacol 74:1224–1234
23. Rahman S, Lopez-Hernandez GY, Corrigall WA, Papke RL (2008) Neuronal nicotinic receptors as brain targets for pharmacotherapy of drug addiction. CNS Neurol Disord Drug Targets 7:422–441
24. Clarke PB (1987) Nicotine and smoking: a perspective from animal studies. Psychopharmacology 92:135–143
25. Damaj MI, Welch SP, Martin BR (1995) In vivo pharmacological effects of dihydro-beta-erythroidine, a nicotinic antagonist, in mice. Psychopharmacology 117:67–73
26. Crooks PA, Dwoskin LP (1997) Contribution of CNS nicotine metabolites to the neuropharmacological effects of nicotine and tobacco smoking. Biochem Pharmacol 54:743–753
27. Benowitz NL (1990) Clinical pharmacology of inhaled drugs of abuse: implications in understanding nicotine dependence. NIDA Res Monogr 99:12–29
28. Lewis DF, Dickins M, Lake BG, Eddershaw PJ, Tarbit MH, Goldfarb PS (1999) Molecular modelling of the human cytochrome P450 isoform CYP2A6 and investigations of CYP2A substrate selectivity. Toxicology 133:1–33
29. Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T (2000) Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 67:57–69
30. Benowitz NL, Kuyt F, Jacob P 3rd, Jones RT, Osman AL (1983) Cotinine disposition and effects. Clin Pharmacol Ther 34:604–611
31. De Schepper PJ, Van Hecken A, Daenens P, Van Rossum JM (1987) Kinetics of cotinine after oral and intravenous administration to man. Eur J Clin Pharmacol 31:583–588
32. Zevin S, Jacob P 3rd, Benowitz N (1997) Cotinine effects on nicotine metabolism. Clin Pharmacol Ther 61:649–654
33. Riah O, Courriere P, Dousset JC, Todeschi N, Labat C (1998) Nicotine is more efficient than cotinine at passing the blood–brain barrier in rats. Cell Mol Neurobiol 18:311–318
34. Bowman ER, Mc KH Jr (1962) Studies on the metabolism of (-)-cotinine in the human. J Pharmacol Exp Ther 135:306–311
35. Borzelleca JF, Bowman ER, Mc KH Jr (1962) Studies on the respiratory and cardiovascular effects of (-)-cotinine. J Pharmacol Exp Ther 137:313–318
36. Benowitz NL, Sharp DS (1989) Inverse relation between serum cotinine concentration and blood pressure in cigarette smokers. Circulation 80:1309–1312
37. Hatsukami D, Lexau B, Nelson D, Pentel PR, Sofuoglu M, Goldman A (1998) Effects of cotinine on cigarette self-administration. Psychopharmacology 138:184–189
38. Hatsukami D, Pentel PR, Jensen J, Nelson D, Allen SS, Goldman A, Rafael D (1998) Cotinine: effects with and without nicotine. Psychopharmacology 135:141–150
39. Buccafusco JJ, Terry AV Jr (2003) The potential role of cotinine in the cognitive and neuroprotective actions of nicotine. Life Sci 72:2931–2942
40. Benowitz NL, Jacob P 3rd, Fong I, Gupta S (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268:296–303
41. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, Funae Y, Shimada N, Kamataki T, Kuroiwa Y (1996) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277:1010–1015
42. Murphy SE, Johnson LM, Pullo DA (1999) Characterization of multiple products of cytochrome P450 2A6-catalyzed cotinine metabolism. Chem Res Toxicol 12:639–645
43. Scherer G, Jarczyk L, Heller WD, Biber A, Neurath GB, Adlkofer F (1988) Pharmacokinetics of nicotine, cotinine, and 3′-hydroxycotinine in cigarette smokers. Klin Wochenschr 66(Suppl 11):5–11
44. Curvall M, Elwin CE, Kazemi-Vala E, Warholm C, Enzell CR (1990) The pharmacokinetics of cotinine in plasma and saliva from non-smoking healthy volunteers. Eur J Clin Pharmacol 38:281–287
45. Keenan RM, Hatsukami DK, Pentel PR, Thompson TN, Grillo MA (1994) Pharmacodynamic effects of cotinine in abstinent cigarette smokers. Clin Pharmacol Ther 55:581–590
46. Dominiak P, Fuchs G, von Toth S, Grobecker H (1985) Effects of nicotine and its major metabolites on blood pressure in anaesthetized rats. Klin Wochenschr 63:90–92
47. Yamamoto KI, Domino EF (1965) Nicotine-induced EEG and behavioral arousal. Int J Neuropharmacol 4:359–373
48. Benowitz NL, Hansson A, Jacob P 3rd (2002) Cardiovascular effects of nasal and transdermal nicotine and cigarette smoking. Hypertension 39:1107–1112
49. Zevin S, Gourlay SG, Benowitz NL (1998) Clinical pharmacology of nicotine. Clin Dermatol 16:557–564
50. Benowitz NL, Jacob P 3rd, Jones RT, Rosenberg J (1982) Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther 221:368–372
51. Benowitz NL, Porchet H, Sheiner L, Jacob P 3rd (1988) Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther 44:23–28
52. Sutherland G, Russell MA, Stapleton J, Feyerabend C, Ferno O (1992) Nasal nicotine spray: a rapid nicotine delivery system. Psychopharmacology 108:512–518
53. Green MS, Jucha E, Luz Y (1986) Blood pressure in smokers and nonsmokers: epidemiologic findings. Am Heart J 111:932–940
54. LaVoie EJ, Shigematsu A, Rivenson A, Mu B, Hoffmann D (1985) Evaluation of the effects of cotinine and nicotine-N’-oxides on the development of tumors in rats initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide. J Natl Cancer Inst 75:1075–1081
55. Terry AV Jr, Hernandez CM, Hohnadel EJ, Bouchard KP, Buccafusco JJ (2005) Cotinine, a neuroactive metabolite of nicotine: potential for treating disorders of impaired cognition. CNS Drug Rev 11:229–252
56. Iarkov A, Appunn D, Echeverria Moran V (2014) Fighting against the chemo brain: cotinine improved cognitive functions, locomotor activity and elevated mood in rats treated with chemotherapy drugs. In: Bay Pines Veterans Affairs Research Day. Bay Pines, FL
57. Grizzell JA, Iarkov AV, Holmes R, Mori T, Echeverria Moran V (2012) Cotinine prevents working memory loss in a mouse model of Posttraumatic stress-induced cognitive impairment. In: Society for neuroscience. New Orleans
58. Zeitlin R, Patel S, Solomon R, Tran J, Weeber EJ, Echeverria V (2012) Cotinine enhances the extinction of contextual fear memory and reduces anxiety after fear conditioning. Behav Brain Res 228:284–293
59. Grebenstein PE, Thompson IE, Rowland NE (2013) The effects of extended intravenous nicotine administration on body weight and meal patterns in male Sprague–Dawley rats. Psychopharmacology 228:359–366
60. Wellman PJ, Marmon MM, Reich S, Ruddle J (1986) Effects of nicotine on body weight, food intake and brown adipose tissue thermogenesis. Pharmacol Biochem Behav 24:1605–1609
61. Audrain-McGovern J, Benowitz NL (2011) Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther 90:164–168
62. Andersson K, Arner P (2001) Systemic nicotine stimulates human adipose tissue lipolysis through local cholinergic and catecholaminergic receptors. Int J Obe Relat Metab Disord 25:1225–1232
63. Hofstetter A, Schutz Y, Jequier E, Wahren J (1986) Increased 24-hour energy expenditure in cigarette smokers. N Engl J Med 314:79–82
64. Cabanac M, Frankham P (2002) Evidence that transient nicotine lowers the body weight set point. Physiol Behav 76:539–542
65. Faraday MM (2002) Rat sex and strain differences in responses to stress. Physiol Behav 75:507–522
66. Faraday MM, Blakeman KH, Grunberg NE (2005) Strain and sex alter effects of stress and nicotine on feeding, body weight, and HPA axis hormones. Pharmacol Biochem Behav 80:577–589
67. Riah O, Dousset JC, Courriere P, Stigliani JL, Baziard-Mouysset G, Belahsen Y (1999) Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol Lett 109:21–29
68. Andersson K, Jansson A, Kuylenstierna F, Eneroth P (1993) Nicotine and its major metabolite cotinine have different effects on aldosterone and prolactin serum levels in the normal male rat. Eur J Pharmacol 228:305–312
69. Lutfy K, Brown MC, Nerio N, Aimiuwu O, Tran B, Anghel A, Friedman TC (2006) Repeated stress alters the ability of nicotine to activate the hypothalamic–pituitary–adrenal axis. J Neurochem 99:1321–1327
70. Gentile NE, Andrekanic JD, Karwoski TE, Czambel RK, Rubin RT, Rhodes ME (2011) Sexually diergic hypothalamic–pituitary–adrenal (HPA) responses to single-dose nicotine, continuous nicotine infusion, and nicotine withdrawal by mecamylamine in rats. Brain Res Bull 85:145–152
71. Matta SG, Singh J, Sharp BM (1990) Catecholamines mediate nicotine-induced adrenocorticotropin secretion via alpha-adrenergic receptors. Endocrinology 127:1646–1655
72. Chen H, Fu Y, Sharp BM (2008) Chronic nicotine self-administration augments hypothalamic–pituitary–adrenal responses to mild acute stress. Neuropsychopharmacology 33:721–730
73. Kubzansky LD, Adler GK (2010) Aldosterone: a forgotten mediator of the relationship between psychological stress and heart disease. Neurosci Biobehav Rev 34:80–86
74. Murck H, Held K, Ziegenbein M, Kunzel H, Koch K, Steiger A (2003) The renin–angiotensin–aldosterone system in patients with depression compared to controls—a sleep endocrine study. BMC Psychiatry 3:15
75. Hlavacova N, Jezova D (2008) Chronic treatment with the mineralocorticoid hormone aldosterone results in increased anxiety-like behavior. Horm Behav 54:90–97
76. Grizzell JA, Iarkov A, Holmes R, Mori T, Echeverria V (2014) Cotinine reduces working memory deficits, depressive-like behavior, and synaptic loss associated with chronic stress in mice. Behav Brain Res (in press)
77. Faraday MM, O’Donoghue VA, Grunberg NE (2003) Effects of nicotine and stress on locomotion in Sprague–Dawley and Long–Evans male and female rats. Pharmacol Biochem Behav 74:325–333
78. Fernandez JW, Grizzell JA, Wecker L (2013) The role of estrogen receptor beta and nicotinic cholinergic receptors in postpartum depression. Prog Neuropsychopharmacol Biol Psychiatry 40:199–206
79. Blackburn CW, Peterson CA, Hales HA, Carrell DT, Jones KP, Urry RL, Peterson CM (1994) Nicotine, but not cotinine, has a direct toxic effect on ovarian function in the immature gonadotropin-stimulated rat. Reproduct Toxicol (Elmsford, NY) 8:325–331
80. Muehlfelder M, Arias-Loza PA, Fritzemeier KH, Pelzer T (2012) Both estrogen receptor subtypes, ERalpha and ERbeta, prevent aldosterone-induced oxidative stress in VSMC via increased NADPH bioavailability. Biochem Biophys Res Commun 423:850–856
81. Risner ME, Goldberg SR, Prada JA, Cone EJ (1985) Effects of nicotine, cocaine and some of their metabolites on schedule-controlled responding by beagle dogs and squirrel monkeys. J Pharmacol Exp Ther 234:113–119
82. Goldberg SR, Risner ME, Stolerman IP, Reavill C, Garcha HS (1989) Nicotine and some related compounds: effects on schedule-controlled behaviour and discriminative properties in rats. Psychopharmacology 97:295–302
83. Brunzell DH, Picciotto MR (2009) Molecular mechanisms underlying the motivational effects of nicotine. Nebr Symp Motiv 55:17–30
84. Caggiula AR, Donny EC, White AR, Chaudhri N, Booth S, Gharib MA, Hoffman A, Perkins KA, Sved AF (2001) Cue dependency of nicotine self-administration and smoking. Pharmacol Biochem Behav 70:515–530
85. Gould TJ, Leach PT (2014) Cellular, molecular, and genetic substrates underlying the impact of nicotine on learning. Neurobiol Learn Mem 107:108–132
86. Davis JA, James JR, Siegel SJ, Gould TJ (2005) Withdrawal from chronic nicotine administration impairs contextual fear conditioning in C57BL/6 mice. J Neurosci 25:8708–8713
87. Davis JA, Porter J, Gould TJ (2006) Nicotine enhances both foreground and background contextual fear conditioning. Neurosci Lett 394:202–205
88. Sartor GC, Aston-Jones G (2014) Post-retrieval extinction attenuates cocaine memories. Neuropsychopharmacology 39:1059–1065
89. Kelamangalath L, Swant J, Stramiello M, Wagner JJ (2007) The effects of extinction training in reducing the reinstatement of drug-seeking behavior: involvement of NMDA receptors. Behav Brain Res 185:119–128
90. Marin MF, Camprodon JA, Dougherty DD (2014) Milad MR. Implications for PTSD treatment and beyond. Depression and anxiety, Device-based brain stimulation to augment fear-extinction
91. Elias GA, Gulick D, Wilkinson DS, Gould TJ (2010) Nicotine and extinction of fear conditioning. Neuroscience 165:1063–1073
92. Kutlu MG, Gould TJ (2014) Acute nicotine delays extinction of contextual fear in mice. Behav Brain Res 263:133–137
93. Smith LN, McDonald CG, Bergstrom HC, Brielmaier JM, Eppolito AK, Wheeler TL, Falco AM, Smith RF (2006) Long-term changes in fear conditioning and anxiety-like behavior following nicotine exposure in adult versus adolescent rats. Pharmacol Biochem Behav 85:91–97
94. Tian S, Gao J, Han L, Fu J, Li C, Li Z (2008) Prior chronic nicotine impairs cued fear extinction but enhances contextual fear conditioning in rats. Neuroscience 153:935–943
95. de Aguiar RB, Parfitt GM, Jaboinski J, Barros DM (2013) Neuroactive effects of cotinine on the hippocampus: behavioral and biochemical parameters. Neuropharmacology 71:292–298
96. Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, Mamcarz M, Wang L, Sattelle DB, Kirschner DA, Mori T, Leblanc RM, Prabhakar R, Arendash GW (2011) Cotinine reduces amyloid-beta aggregation and improves memory in Alzheimer’s disease mice. J Alzheimers Dis 24:817–835
97. Patel S, Grizzell JA, Holmes R, Zeitlin R, Solomon R, Lutton TL, Rohani A, Charry L, Iarkov A, Mori T, Echeverria Moran V (2014) Cotinine halts the advance of Alzheimer's disease-like pathology and associated depressive-like behavior in Tg6799 mice. Front Aging Neurosci 6:162
98. Terry AV Jr, Buccafusco JJ, Schade RF, Vandenhuerk L, Callahan PM, Beck WD, Hutchings EJ, Chapman JM, Li P, Bartlett MG (2012) The nicotine metabolite, cotinine, attenuates glutamate (NMDA) antagonist-related effects on the performance of the five choice serial reaction time task (5C-SRTT) in rats. Biochem Pharmacol 83:941–951
99. Buccafusco JJ, Terry AV Jr (2009) A reversible model of the cognitive impairment associated with schizophrenia in monkeys: potential therapeutic effects of two nicotinic acetylcholine receptor agonists. Biochem Pharmacol 78:852–862
100. Xue MQ, Liu XX, Zhang YL, Gao FG (2014) Nicotine exerts neuroprotective effects against beta-amyloid-induced neurotoxicity in SH-SY5Y cells through the Erk1/2-p38-JNK-dependent signaling pathway. Int J Mol Med 33:925–933
101. French KL, Granholm AC, Moore AB, Nelson ME, Bimonte-Nelson HA (2006) Chronic nicotine improves working and reference memory performance and reduces hippocampal NGF in aged female rats. Behav Brain Res 169:256–262
102. Levin ED, Torry D (1996) Acute and chronic nicotine effects on working memory in aged rats. Psychopharmacology 123:88–97
103. Levin ED, Kaplan S, Boardman A (1997) Acute nicotine interactions with nicotinic and muscarinic antagonists: working and reference memory effects in the 16-arm radial maze. Behav Pharmacol 8:236–242
104. Soto D, Hodsoll J, Rotshtein P, Humphreys GW (2008) Automatic guidance of attention from working memory. Trends Cogn Sci 12:342–348
105. Floresco SB, Jentsch JD (2011) Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology 36:227–250
106. Levin ED, Bushnell PJ, Rezvani AH (2011) Attention-modulating effects of cognitive enhancers. Pharmacol Biochem Behav 99:146–154
107. Sanchez-Roige S, Pena-Oliver Y, Stephens DN (2012) Measuring impulsivity in mice: the five-choice serial reaction time task. Psychopharmacology 219:253–270
108. Buccafusco JJ, Beach JW, Terry AV Jr (2009) Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther 328:364–370
109. Buccafusco JJ, Jackson WJ, Jonnala RR, Terry AV Jr (1999) Differential improvement in memory-related task performance with nicotine by aged male and female rhesus monkeys. Behav Pharmacol 10:681–690
110. Burriss L, Ayers E, Ginsberg J, Powell DA (2008) Learning and memory impairment in PTSD: relationship to depression. Depress Anxiety 25:149–157
111. Veltmeyer MD, Clark CR, McFarlane AC, Moores KA, Bryant RA, Gordon E (2009) Working memory function in post-traumatic stress disorder: an event-related potential study. Clin Neurophysiol 120:1096–1106
112. Elzinga BM, Bremner JD (2002) Are the neural substrates of memory the final common pathway in posttraumatic stress disorder (PTSD)? J Affect Disord 70:1–17
113. Johnsen GE, Asbjornsen AE (2009) Verbal learning and memory impairments in posttraumatic stress disorder: the role of encoding strategies. Psychiatry Res 165:68–77
114. Jodar L, Takahashi M, Kaneto H (1995) Effects of footshock-, psychological- and forced swimming-stress on the learning and memory processes: involvement of opioidergic pathways. Jpn J Pharmacol 67:143–147
115. Naudon L, Jay TM (2005) Opposite behaviours in the forced swimming test are linked to differences in spatial working memory performances in the rat. Neuroscience 130:285–293
116. Diamond DM, Park CR, Heman KL, Rose GM (1999) Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus 9:542–552
117. Aleisa AM, Alzoubi KH, Gerges NZ, Alkadhi KA (2006) Nicotine blocks stress-induced impairment of spatial memory and long-term potentiation of the hippocampal CA1 region. Int J Neuropsychopharmacol 9:417–426
118. Alzoubi KH, Srivareerat M, Tran TT, Alkadhi KA (2013) Role of alpha7- and alpha4beta2-nAChRs in the neuroprotective effect of nicotine in stress-induced impairment of hippocampus-dependent memory. Int J Neuropsychopharmacol 16:1105–1113
119. Zhang K, Song X, Xu Y, Li X, Liu P, Sun N, Zhao X, Liu Z, Xie Z, Peng J (2013) Continuous GSK-3beta overexpression in the hippocampal dentate gyrus induces prodepressant-like effects and increases sensitivity to chronic mild stress in mice. J Affect Disord 146:45–52
120. Duman RS (2014) Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections. Depress Anxiety 31:291–296
121. Li X, Bijur GN, Jope RS (2002) Glycogen synthase kinase-3beta, mood stabilizers, and neuroprotection. Bipolar Disord 4:137–144
122. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68–72
123. Djuric VJ, Dunn E, Overstreet DH, Dragomir A, Steiner M (1999) Antidepressant effect of ingested nicotine in female rats of Flinders resistant and sensitive lines. Physiol Behav 67:533–537
124. Semba J, Mataki C, Yamada S, Nankai M, Toru M (1998) Antidepressantlike effects of chronic nicotine on learned helplessness paradigm in rats. Biol Psychiatry 43:389–391
125. Tizabi Y, Getachew B, Rezvani AH, Hauser SR, Overstreet DH (2009) Antidepressant-like effects of nicotine and reduced nicotinic receptor binding in the fawn-hooded rat, an animal model of co-morbid depression and alcoholism. Prog Neuropsychopharmacol Biol Psychiatry 33:398–402
126. Hayase T (2008) Nicotine (NC)-induced “depressive” behavioral symptoms and effects of antidepressants including cannabinoids (CBs). J Toxicol Sci 33:555–564
127. Hayase T (2007) Chronologically overlapping occurrences of nicotine-induced anxiety- and depression-related behavioral symptoms: effects of anxiolytic and cannabinoid drugs. BMC Neurosci 8:76
128. Hayase T (2013) Working memory- and anxiety-related behavioral effects of repeated nicotine as a stressor: the role of cannabinoid receptors. BMC Neurosci 14:20
129. Philip NS, Carpenter LL, Tyrka AR, Price LH (2010) Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature. Psychopharmacology 212:1–12
130. Picciotto MR, Addy NA, Mineur YS, Brunzell DH (2008) It is not “either/or”: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood. Prog Neurobiol 84:329–342
131. Echeverria V, Zeitlin R (2012) Cotinine: a potential new therapeutic agent against Alzheimer’s disease. CNS Neurosci Ther 18:517–523
132. Gao J, Adam BL, Terry AV Jr (2014) Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer’s disease. Bioorg Med Chem Lett 24:1472–1478
133. Burgess S Zeitlin R, Gamble-George J, Echeverria V (2012) Cotinine is neuroprotective against beta-amyloid toxicity. J Clin Toxicol 4:T466
134. Echeverria V, Zeitlin R, Burgess S, Patel S, Barman A, Thakur G, Mamcarz M, Wang L, Sattelle DB, Kirschner DA, Mori T, Leblanc RM, Prabhakar R, Arendash GW (2011) Cotinine reduces amyloid-b aggregation and improves memory in Alzheimer’s disease mice. J Alzheimers Dis 23:1–19
135. Nie H, Wang Z, Zhao W, Lu J, Zhang C, Lok K, Wang Y, Shen H, Xu Z, Yin M (2013) New nicotinic analogue ZY-1 enhances cognitive functions in a transgenic mice model of Alzheimer’s disease. Neurosci Lett 537:29–34
136. Levin ED (2002) Nicotinic receptor subtypes and cognitive function. J Neurobiol 53:633–640
137. Taly A, Corringer PJ, Guedin D, Lestage P, Changeux JP (2009) Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system. Nat Rev Drug Discov 8:733–750
138. Pakkanen JS, Jokitalo E, Tuominen RK (2005) Up-regulation of beta2 and alpha7 subunit containing nicotinic acetylcholine receptors in mouse striatum at cellular level. Eur J Neurosci 21:2681–2691
139. Broide RS, Leslie FM (1999) The alpha7 nicotinic acetylcholine receptor in neuronal plasticity. Mol Neurobiol 20:1–16
140. Picciotto MR, Caldarone BJ, Brunzell DH, Zachariou V, Stevens TR, King SL (2001) Neuronal nicotinic acetylcholine receptor subunit knockout mice: physiological and behavioral phenotypes and possible clinical implications. Pharmacol Ther 92:89–108
141. Katz BT, Thesleff S (1957) Study of the desensitization produced by acetylcholine at the motor end-plate. J Physiol (London) 138:63–80
142. Ke L, Eisenhour CM, Bencherif M, Lukas RJ (1998) Effects of chronic nicotine treatment on expression of diverse nicotinic acetylcholine receptor subtypes. I. Dose- and time-dependent effects of nicotine treatment. J Pharmacol Exp Ther 286:825–840
143. Briggs CA, McKenna DG (1998) Activation and inhibition of the human alpha7 nicotinic acetylcholine receptor by agonists. Neuropharmacology 37:1095–1102
144. Reitstetter R, Lukas RJ, Gruener R (1999) Dependence of nicotinic acetylcholine receptor recovery from desensitization on the duration of agonist exposure. J Pharmacol Exp Ther 289:656–660
145. Jeanclos EM, Lin L, Treuil MW, Rao J, DeCoster MA, Anand R (2001) The chaperone protein 14-3-3eta interacts with the nicotinic acetylcholine receptor alpha 4 subunit. Evidence for a dynamic role in subunit stabilization. J Biol Chem 276:28281–28290
146. Lin L, Jeanclos EM, Treuil M, Braunewell KH, Gundelfinger ED, Anand R (2002) The calcium sensor protein visinin-like protein-1 modulates the surface expression and agonist sensitivity of the alpha 4beta 2 nicotinic acetylcholine receptor. J Biol Chem 277:41872–41878
147. Wang H, Sun X (2005) Desensitized nicotinic receptors in brain. Brain Res 48:420–437
148. Cheng MH, Xu Y, Tang P (2009) Anionic lipid and cholesterol interactions with alpha4beta2 nAChR: insights from MD simulations. J Phys Chem B 113:6964–6970
149. Rowell PP, Duggan DS (1998) Long-lasting inactivation of nicotinic receptor function in vitro by treatment with high concentrations of nicotine. Neuropharmacology 37:103–111
150. Sakmann B, Patlak J, Neher E (1980) Single acetylcholine-activated channels show burst-kinetics in presence of desensitizing concentrations of agonist. Nature 286:71–73
151. Orr-Urtreger A, Broide RS, Kasten MR, Dang H, Dani JA, Beaudet AL, Patrick JW (2000) Mice homozygous for the L250T mutation in the alpha7 nicotinic acetylcholine receptor show increased neuronal apoptosis and die within 1 day of birth. J Neurochem 74:2154–2166
152. Abdulla FA, Bradbury E, Calaminici MR, Lippiello PM, Wonnacott S, Gray JA, Sinden JD (1996) Relationship between up-regulation of nicotine binding sites in rat brain and delayed cognitive enhancement observed after chronic or acute nicotinic receptor stimulation. Psychopharmacology 124:323–331
153. Werkheiser JL, Sydserff S, Hubbs SJ, Ding M, Eisman MS, Perry D, Williams AJ, Smith JS, Mrzljak L, Maier DL (2011) Ultra-low exposure to alpha-7 nicotinic acetylcholine receptor partial agonists elicits an improvement in cognition that corresponds with an increase in alpha-7 receptor expression in rodents: implications for low dose clinical efficacy. Neuroscience 186:76–87
154. Gould TJ, Portugal GS, Andre JM, Tadman MP, Marks MJ, Kenney JW, Yildirim E, Adoff M (2012) The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. Neuropharmacology 62:2118–2125
155. Miwa JM, Freedman R, Lester HA (2011) Neural systems governed by nicotinic acetylcholine receptors: emerging hypotheses. Neuron 70:20–33
156. Collins AC, Bhat RV, Pauly JR, Marks MJ (1990) Modulation of nicotine receptors by chronic exposure to nicotinic agonists and antagonists. Ciba Found Symp 152:68–82 (discussion 82--66)
157. Ke L, Lukas RJ (1996) Effects of steroid exposure on ligand binding and functional activities of diverse nicotinic acetylcholine receptor subtypes. J Neurochem 67:1100–1112
158. Enrico P, Sirca D, Mereu M, Peana AT, Mercante B, Diana M (2013) Acute restraint stress prevents nicotine-induced mesolimbic dopaminergic activation via a corticosterone-mediated mechanism: a microdialysis study in the rat. Drug Alcohol Depend 127:8–14
159. Vainio PJ, Tuominen RK (2001) Cotinine binding to nicotinic acetylcholine receptors in bovine chromaffin cell and rat brain membranes. Nicotine Tob Res 3:177–182
160. Thomsen MS, Mikkelsen JD (2012) Type I and II positive allosteric modulators differentially modulate agonist-induced up-regulation of alpha7 nicotinic acetylcholine receptors. J Neurochem 123:73–83
161. Wildeboer-Andrud KM, Zheng L, Choo KS, Stevens KE (2014) Cotinine impacts sensory processing in DBA/2 mice through changes in the conditioning amplitude. Pharmacol Biochem Behav 117:144–150
162. Ng HJ, Whittemore ER, Tran MB, Hogenkamp DJ, Broide RS, Johnstone TB, Zheng L, Stevens KE, Gee KW (2007) Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc Natl Acad Sci USA 104:8059–8064
163. Ludwig J, Hoffle-Maas A, Samochocki M, Luttmann E, Albuquerque EX, Fels G, Maelicke A (2010) Localization by site-directed mutagenesis of a galantamine binding site on alpha7 nicotinic acetylcholine receptor extracellular domain. J Recept Signal Transduct Res 30:469–483
164. Zwart R, De Filippi G, Broad LM, McPhie GI, Pearson KH, Baldwinson T, Sher E (2002) 5-Hydroxyindole potentiates human alpha 7 nicotinic receptor-mediated responses and enhances acetylcholine-induced glutamate release in cerebellar slices. Neuropharmacology 43:374–384
165. Hajos M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE (2005) The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats. J Pharmacol Exp Ther 312:1213–1222
166. Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, Lawson JA, Rutherford-Root KL, Berkenpas MB, Hoffmann WE, Piotrowski DW, Groppi VE, Allaman G, Ogier R, Bertrand S, Bertrand D, Arneric SP (2005) A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization. J Neurosci 25:4396–4405
167. Sun F, Jin K, Uteshev VV (2013) A type-II positive allosteric modulator of alpha7 nAChRs reduces brain injury and improves neurological function after focal cerebral ischemia in rats. PLoS One 8:e73581
168. Gronlien JH, Hakerud M, Ween H, Thorin-Hagene K, Briggs CA, Gopalakrishnan M, Malysz J (2007) Distinct profiles of alpha7 nAChR positive allosteric modulation revealed by structurally diverse chemotypes. Mol Pharmacol 72:715–724
169. Han ZY, Le Novere N, Zoli M, Hill JA Jr, Champtiaux N, Changeux JP (2000) Localization of nAChR subunit mRNAs in the brain of Macaca mulatta. Eur J Neurosci 12:3664–3674
170. Narahashi T, Fenster CP, Quick MW, Lester RA, Marszalec W, Aistrup GL, Sattelle DB, Martin BR, Levin ED (2000) Symposium overview: mechanism of action of nicotine on neuronal acetylcholine receptors, from molecule to behavior. Toxicol Sci 57:193–202
171. Yakel JL (2013) Cholinergic receptors: functional role of nicotinic ACh receptors in brain circuits and disease. Pflugers Arch 465:441–450
172. Vainio PJ, Tornquist K, Tuominen RK (2000) Cotinine and nicotine inhibit each other’s calcium responses in bovine chromaffin cells. Toxicol Appl Pharmacol 163:183–187
173. Shin LM, Orr SP, Carson MA, Rauch SL, Macklin ML, Lasko NB, Peters PM, Metzger LJ, Dougherty DD, Cannistraro PA, Alpert NM, Fischman AJ, Pitman RK (2004) Regional cerebral blood flow in the amygdala and medial prefrontal cortex during traumatic imagery in male and female Vietnam veterans with PTSD. Arch Gen Psychiatry 61:168–176
174. Gilbertson MW, Shenton ME, Ciszewski A, Kasai K, Lasko NB, Orr SP, Pitman RK (2002) Smaller hippocampal volume predicts pathologic vulnerability to psychological trauma. Nat Neurosci 5:1242–1247
175. Bremner JD (2006) Stress and brain atrophy. CNS Neurol Disord Drug Targets 5:503–512
176. Dwoskin LP, Teng L, Buxton ST, Crooks PA (1999) (S)-(-)-Cotinine, the major brain metabolite of nicotine, stimulates nicotinic receptors to evoke [3H]dopamine release from rat striatal slices in a calcium-dependent manner. J Pharmacol Exp Ther 288:905–911
177. Fuxe K, Everitt BJ, Hokfelt T (1979) On the action of nicotine and cotinine on central 5-hydroxytryptamine neurons. Pharmacol Biochem Behav 10:671–677
178. Kim DO, Yang XM, Ye Y (2003) A subpopulation of dorsal raphe nucleus neurons retrogradely labeled with cholera toxin-B injected into the inner ear. Exp Brain Res 153:514–521
179. Sesack SR, Deutch AY, Roth RH, Bunney BS (1989) Topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study with Phaseolus vulgaris leucoagglutinin. J Comp Neurol 290:213–242
180. Vertes RP (2004) Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 51:32–58
181. Royer S, Martina M, Pare D (1999) An inhibitory interface gates impulse traffic between the input and output stations of the amygdala. J Neurosci 19:10575–10583
182. Ma Z, Strecker RE, McKenna JT, Thakkar MM, McCarley RW, Tao R (2005) Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats. Neuroscience 135:949–958
183. Reuben M, Clarke PB (2000) Nicotine-evoked [3H]5-hydroxytryptamine release from rat striatal synaptosomes. Neuropharmacology 39:290–299
184. Tucci SA, Genn RF, File SE (2003) Methyllycaconitine (MLA) blocks the nicotine evoked anxiogenic effect and 5-HT release in the dorsal hippocampus: possible role of alpha7 receptors. Neuropharmacology 44:367–373
185. Andreasen JT, Redrobe JP (2009) Antidepressant-like effects of nicotine and mecamylamine in the mouse forced swim and tail suspension tests: role of strain, test and sex. Behav Pharmacol 20:286–295
186. Andreasen JT, Redrobe JP (2009) Nicotine, but not mecamylamine, enhances antidepressant-like effects of citalopram and reboxetine in the mouse forced swim and tail suspension tests. Behav Brain Res 197:150–156
187. Andreasen JT, Redrobe JP, Nielsen EO (2012) Combined alpha7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987. Pharmacol Biochem Behav 100:624–629
188. Beaulieu JM, Zhang X, Rodriguiz RM, Sotnikova TD, Cools MJ, Wetsel WC, Gainetdinov RR, Caron MG (2008) Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proc Natl Acad Sci USA 105:1333–1338
189. Beaulieu JM, Gainetdinov RR, Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327–347
190. Beaulieu JM (2012) A role for Akt and glycogen synthase kinase-3 as integrators of dopamine and serotonin neurotransmission in mental health. J Psychiatry Neurosci 37:7–16
191. Del’Guidice T, Beaulieu JM (2010) Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses. Med Sci M/S 26:647–651
192. Chakraborty A, Latapy C, Xu J, Snyder SH, Beaulieu JM (2013) Inositol hexakisphosphate kinase-1 regulates behavioral responses via GSK3 signaling pathways. Mol Psychiatry 19:284–293
193. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261–273
194. Beaulieu JM, Del’guidice T, Sotnikova TD, Lemasson M, Gainetdinov RR (2011) Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors. Front Mol Neurosci 4:38
195. Jope RS (2011) Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. Front Mol Neurosci 4:16
196. Freland L, Beaulieu JM (2012) Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 5:14
197. Emamian ES, Hall D, Birnbaum MJ, Karayiorgou M, Gogos JA (2004) Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36:131–137
198. Li YC, Xi D, Roman J, Huang YQ, Gao WJ (2009) Activation of glycogen synthase kinase-3 beta is required for hyperdopamine and D2 receptor-mediated inhibition of synaptic NMDA receptor function in the rat prefrontal cortex. J Neurosci 29:15551–15563
199. Peineau S, Bradley C, Taghibiglou C, Doherty A, Bortolotto ZA, Wang YT, Collingridge GL (2008) The role of GSK-3 in synaptic plasticity. Br J Pharmacol 153(Suppl 1):S428–S437
200. Logan CY, Nusse R (2004) The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 20:781–810
201. Arrazola MS, Varela-Nallar L, Colombres M, Toledo EM, Cruzat F, Pavez L, Assar R, Aravena A, Gonzalez M, Montecino M, Maass A, Martinez S, Inestrosa NC (2009) Calcium/calmodulin-dependent protein kinase type IV is a target gene of the Wnt/beta-catenin signaling pathway. J Cell Physiol 221:658–667
202. Brunzell DH, Russell DS, Picciotto MR (2003) In vivo nicotine treatment regulates mesocorticolimbic CREB and ERK signaling in C57Bl/6J mice. J Neurochem 84:1431–1441
203. Dajas-Bailador FA, Soliakov L, Wonnacott S (2002) Nicotine activates the extracellular signal-regulated kinase 1/2 via the alpha7 nicotinic acetylcholine receptor and protein kinase A, in SH-SY5Y cells and hippocampal neurones. J Neurochem 80:520–530
204. Steiner RC, Heath CJ, Picciotto MR (2007) Nicotine-induced phosphorylation of ERK in mouse primary cortical neurons: evidence for involvement of glutamatergic signaling and CaMKII. J Neurochem 103:666–678
205. Nakayama H, Shimoke K, Isosaki M, Satoh H, Yoshizumi M, Ikeuchi T (2006) Subtypes of neuronal nicotinic acetylcholine receptors involved in nicotine-induced phosphorylation of extracellular signal-regulated protein kinase in PC12h cells. Neurosci Lett 392:101–104